Product information and disease descriptionPlace of product in therapyApproaches to treatment
Heterogeneity of treatment effect
7 evidence topics · 8 sources
Company-presented survival by onset category and baseline miglustat use
Company-presented survival by baseline disease burden in infantile-onset disease
Company-presented disease progression by time from neurological onset to treatment
Neurological onset at 6 years or older: outside the approved indication
Background miglustat or leucine use and the intravenous HPβCD treatment effect in TransportNPC
Subtype differences for the other approved therapies: state Medicaid drug class review
Guideline statements on predicting treatment response by subtype
“Additionally, predicting patient treatment responses remains challenging, further supporting the potential benefits of a combined therapeutic approach” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Future research priorities must focus on identifying the optimal timing for individual therapies during disease progression and understanding the most effective treatment combinations for various NPC patient subtypes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote